An evaluation of the cytochrome P450 inhibition potential of lisdexamfetamine in human liver microsomes

Drug Metabolism and Disposition

Volumn 35, Issue 1, 2007, Pages 180-184

  Krishnan, Suma ^a,b   Moncrief, Scott ^a  

^a New River Pharmaceuticals   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; LISDEXAMFETAMINE; MEPHENYTOIN; MIDAZOLAM; PHENACETIN; TESTOSTERONE; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MALE; METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROAMPHETAMINE; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; NADP;

EID: 33845930884     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011973     Document Type: Article

References (23)

1. American Academy of Pediatrics (2000) Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 105:1158-1170.
2. Bach MV, Coutts RT, and Baker GB (1999) Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 29:719-732.
3. Centers for Disease Control and Prevention (2005) National Center for Health Statistics. FASTATS - Attention Deficit Hyperactivity Disorder. Available at: http://www.cdc.gov/nchs/fastats/adhd.htm. Accessed December 9, 2005.
4. Cupp MJ and Tracy TS (1998) Cytochrome P450: new nomenclature and clinical implications. Am Fam Phys 57:107-116.
5. Dulcan M (1997) Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 36 (Suppl 10): 85S-121S.
6. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
7. Goldstein JA, Faletto MB, Romkes-Sparks M, Kitareewan S, Raucy JL, Lasker JM, and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
8. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by member of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
9. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
10. Jasinski DR and Krishnan S (2006) Abuse liability of intravenous L-lysine-d-amphetamine (NRP104), in Abstracts, 68th Annual Scientific Meeting of the College on Problems of Drug Dependence, 2006 July 17-22, Scottsdale, AZ.
11. Kerry NL, Somogyi AA, Bochner F, and Mikus G (1994) The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. Br J Clin Pharmacol 38:243-248.
12. Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, and Chiba K (1999) Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 27:860-865.
13. Mickle T, Krishnan S, Bishop B, Lauderback C, Moncrief JS, Oberlender RO, and Piccariello T (2006) inventors, New River Pharmaceuticals, Inc., assignee. Abuse-resistant amphetamine compounds. US patent 7,105,486. 2006 Sep 12.
14. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, and Wolf CR (1990) Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371.
15. Nedelcheva V and Gut I (1994) P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24:1151-1175.
16. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450-IIE1. Chem Res Toxicol 3:566-573.
17. Prough RA and Spearman ME (1987) Endogenous and dietary chemicals: metabolism and interaction with cytochrome P450, in Mammalian Cytochromes P450 (Guengerich FP ed) vol 2, pp 153-172, CRC Press, Boca Raton, FL.
18. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
19. Slaughter RL and Edwards DJ (1995) Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619-624.
20. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, and Birkett DJ (1991) Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P450 2C9. Biochem Biophys Res Commun 175:1112-1118.
21. Waxman DJ, Attisano C, Guengerich FP, and Lapenson DP (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P450 enzyme. Arch Biochem Biophys 263:424-436.
22. Wrighton SA, Stevens JC, Becker GW, and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240-245.
23. Yang CS and Lu AYH (1987) The diversity of substrates for cytochrome P450, in Mammalian Cytochromes P450 (Guengerich FP ed) vol 2, pp 1-18, CRC Press, Boca Raton, FL.